HERPET- A Novel PET Imaging Study of HER2 in Breast Cancer

This mechanistic study will be the first study to assess the efficacy of \[18F\]GE-226 to target HER2 expression in patients with metastatic breast cancer. The study will establish the pharmacokinetics of \[18F\]GE-226 and the optimum time-point for performing static scans in this patient population.

Trial Details

NCT ID
NCT03827317
Phase
NA
Sponsor
Imperial College London
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • [18F]GE-226
Locations (sample)
  • London, United Kingdom|51.50853,-0.12574

Key Eligibility Criteria

  • Female patients with a histological diagnosis of breast cancer with known HER2 status ((8 positive and 8 negative).
  • Written informed consent prior to admission in the study.
  • Target lesion diameter of ≥15mm that has not been previously irradiated.
  • Female patients aged ≥ 18 years of age.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →